Publications

Journal Article
Comparative Study
Ppublish 5 citations
Electronic publication date
July 3, 2025

View on Pubmed.gov 40388602 | View on doi.org 10.1093/gerona/...

Comparative Effectiveness of Metformin Versus Sulfonylureas on Exceptional Longevity in Women With Type 2 Diabetes: Target Trial Emulation.

Search for publications in this journal J Gerontol A Biol Sci Med Sci

Abstract

BACKGROUND

The association of metformin with mortality has been mixed, and no prior study has determined whether metformin initiation is associated with exceptional longevity, defined as survival to ages 90 and older.

METHODS

We performed a new-user, active comparator cohort study using the target trial emulation framework among the Women's Health Initiative cohort to determine whether metformin versus sulfonylurea initiation was associated with exceptional longevity (survival to age 90). We identified participants ≥60 years with incident type 2 diabetes and no history of hypoglycemic agents or insulin prior to treatment initiation to perform intention-to-treat analyses. We used 1:1 propensity score matching on demographic characteristics, lifestyle behaviors, diabetes duration, comorbidities (hypertension, cardiovascular disease, chronic obstructive pulmonary disease, and cancer), body mass index, and concomitant medications to balance treatment groups on key confounders.

RESULTS

Among 438 propensity score-matched women with type 2 diabetes, the incidence rate of death before age 90 per 100 person-years in women initiating metformin monotherapy was 3.7 (95% CI: 3.1-4.4) compared with 5.0 (95% CI: 4.2-5.8) for sulfonylurea monotherapy. The adjusted risk of death before age 90 was 30% lower for initiation of metformin monotherapy versus sulfonylurea monotherapy (hazard ratio, 0.70; 95% CI: 0.56-0.88).

CONCLUSIONS

In this first target trial emulation of metformin and exceptional longevity, we found that metformin initiation increased exceptional longevity compared with sulfonylurea initiation among women with type 2 diabetes. Because this comparison was not made to placebo in a randomized controlled trial and given the observational design with potential for residual confounding, causality cannot be inferred.

References

JAMA. 2023 Apr 25;329(16):1376-1385

Ann Epidemiol. 2003 Oct;13(9 Suppl):S122-8

Am J Epidemiol. 2012 Feb 15;175(4):250-62

Diabetes Care. 2018 Jan;41(1):69-78

Conflict of interest statement

No conflict of interest statement provided.

MeSH

Specialties

Substances

Copyright

© The Author(s) 2025. Published by Oxford University Press on behalf of the Gerontological Society of America.